Executive Director, Toxicology

• Guide internal strategy and external collaborations to ensure Recursion's toxicology and safety science remains state-of-the-art, driven by the mantra to "predict more, test less."
• Provide pivotal support to Discovery teams, expertly guiding them through exploratory small molecule safety studies toward Development Candidate (DC) nomination.
• Support Development teams in successfully navigating regulatory (GLP / IND-enabling) small molecule studies through First-in-Human (FIH) trials and beyond.
• Partner with data science, AI, and machine learning experts to design, deploy, and leverage state-of-the-art computational and predictive tools that generate robust, clinically-relevant translational datasets.

You will lead a team responsible for embedding modern, data-driven decision-making into drug progression, ultimately accelerating Recursion's mission to decode biology to radically improve lives by positioning the company at the forefront of shifting away from traditional pre-clinical studies toward highly predictive human models.

• Ph.D. is strongly preferred together with accreditation such as ERT or DABT.
• Experience working at/with a mixture of company types (CRO, large pharma, and biotech).
• Proven track record of supporting programs from preclinical discovery into clinical development, specifically for small molecule drugs.
• Demonstrated ability to lead interdisciplinary, cross-functional teams in a complex organization with excellent communication, presentation, and negotiation skills.

Estimated annual base range of £134,200 to £172,100 (GBP), plus eligibility for annual bonus and equity compensation, and a comprehensive benefits package. The company values include acting boldly with integrity, caring deeply, learning actively, moving with urgency, taking ownership, and being One Recursion through cross-functional collaboration.

Recursion is a clinical stage TechBio company leading the space by decoding biology to radically improve lives through its Recursion OS platform, which generates one of the world's largest proprietary biological and chemical datasets and uses machine learning to advance the future of medicine.